Loading stock data…
MXCT
$0.82-0.03 (-3.13%)
Market ClosedLast close May 11
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MaxCyte, Inc. in the Healthcare sector is trading at $0.82. The stock is currently near its 52-week low of $0.64, remaining 36.2% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why MXCT maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.82
Potential Upside
5%
Whystock Fair Value$0.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$91.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.78%
Volume
Today's trading volume
333,957
Recent News
MaxCyte, Inc. Q4 2025 Earnings Call Summary
Moby summary of MaxCyte, Inc.'s Q4 2025 earnings call
MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ...
Despite a challenging year with a 15% revenue decline, MaxCyte Inc (MXCT) focuses on strategic innovations and maintains a strong financial position.
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
Maher Masoud: Thank you, Erik. Good afternoon, everyone, thank you for joining MaxCyte, Inc.'s fourth quarter and full year 2025 earnings call. 2025 presented a challenging operating environment; it was also a year of meaningful progress for MaxCyte, Inc. We continue to sign new strategic platform licenses, SPLs as we call them, and support customers in advancing drugs to the clinic.
MaxCyte Q4 Earnings Call Highlights
MaxCyte (NASDAQ:MXCT) executives told investors the company made “meaningful progress” in 2025 despite a difficult operating environment, highlighting continued strategic platform license (SPL) activity, integration of the SeQure Dx acquisition, cost restructuring, and the February launch of a new r
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of +25.00% and -17.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?